JP2016539993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539993A5 JP2016539993A5 JP2016538082A JP2016538082A JP2016539993A5 JP 2016539993 A5 JP2016539993 A5 JP 2016539993A5 JP 2016538082 A JP2016538082 A JP 2016538082A JP 2016538082 A JP2016538082 A JP 2016538082A JP 2016539993 A5 JP2016539993 A5 JP 2016539993A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- group
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000001424 substituent group Chemical group 0.000 claims 21
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000024340 acute graft versus host disease Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000036566 epidermal hyperplasia Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914086P | 2013-12-10 | 2013-12-10 | |
| US61/914,086 | 2013-12-10 | ||
| PCT/US2014/069494 WO2015089152A1 (en) | 2013-12-10 | 2014-12-10 | N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016539993A JP2016539993A (ja) | 2016-12-22 |
| JP2016539993A5 true JP2016539993A5 (enExample) | 2018-01-25 |
Family
ID=53371792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538082A Pending JP2016539993A (ja) | 2013-12-10 | 2014-12-10 | Ｎ−置換ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9914706B2 (enExample) |
| EP (1) | EP3080087B1 (enExample) |
| JP (1) | JP2016539993A (enExample) |
| AU (1) | AU2014363907B2 (enExample) |
| CA (1) | CA2931792A1 (enExample) |
| WO (1) | WO2015089152A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2639439T3 (es) | 2010-12-08 | 2017-10-26 | Lycera Corporation | Inhibidores de F1F0-ATPasas de tipo pirazolilguanidina y sus usos terapéuticos de éstos |
| WO2015089149A1 (en) | 2013-12-10 | 2015-06-18 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof |
| AU2014363907B2 (en) | 2013-12-10 | 2018-10-04 | Lycera Corporation | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
| JP2016539983A (ja) * | 2013-12-10 | 2016-12-22 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | アルキルピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4977189A (en) | 1986-05-07 | 1990-12-11 | American Cyanamid Company | Substituted guanidinedicarbonyl derivatives |
| JPH07188197A (ja) | 1993-11-17 | 1995-07-25 | Fujisawa Pharmaceut Co Ltd | オキサゾール誘導体 |
| DE4344550A1 (de) | 1993-12-24 | 1995-06-29 | Hoechst Ag | Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen |
| JPH0888197A (ja) | 1994-09-16 | 1996-04-02 | Hitachi Ltd | ２−６族化合物半導体用電極 |
| US7041702B1 (en) | 1997-10-21 | 2006-05-09 | Scion Pharmaceuticals, Inc. | Pharmaceutically active compounds and methods of use |
| AU760174B2 (en) | 1999-02-09 | 2003-05-08 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
| US7276348B2 (en) | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
| CA2377527A1 (en) | 1999-07-15 | 2001-01-25 | Sumitomo Pharmaceuticals Co., Ltd. | Heteroaromatic ring compounds |
| AR034257A1 (es) | 2000-06-30 | 2004-02-18 | Du Pont Pharm Co | Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas |
| WO2003050261A2 (en) | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
| US20040009972A1 (en) | 2002-06-17 | 2004-01-15 | Ding Charles Z. | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
| AU2003295402A1 (en) | 2002-11-06 | 2004-06-03 | Bristol-Myers Squibb Company | Acyl guanidine compounds and use thereof |
| WO2004050610A2 (en) | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
| DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
| US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| US20050272723A1 (en) | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| TW200612948A (en) | 2004-07-01 | 2006-05-01 | Synta Pharmaceuticals Corp | 2-substituted heteroaryl compounds |
| JP5264716B2 (ja) | 2006-06-09 | 2013-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物および方法 |
| ES2614498T3 (es) | 2007-09-14 | 2017-05-31 | The Regents Of The University Of Michigan | Inhibidores de ATPasa F1F0 y métodos relacionados |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| KR100982661B1 (ko) | 2008-04-22 | 2010-09-17 | 전남대학교산학협력단 | 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법 |
| WO2010030891A2 (en) | 2008-09-11 | 2010-03-18 | The Regents Of The University Of Michigan | Aryl guanidine f1f0-atpase inhibitors and related methods |
| WO2012078869A1 (en) | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| ES2639439T3 (es) | 2010-12-08 | 2017-10-26 | Lycera Corporation | Inhibidores de F1F0-ATPasas de tipo pirazolilguanidina y sus usos terapéuticos de éstos |
| AU2011338302A1 (en) | 2010-12-08 | 2013-07-11 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
| US9169199B2 (en) | 2010-12-08 | 2015-10-27 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
| US9221814B2 (en) | 2012-06-08 | 2015-12-29 | Lycera Corporation | Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof |
| US9920012B2 (en) | 2012-06-08 | 2018-03-20 | Lycera Corporation | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
| EP2861225A4 (en) | 2012-06-08 | 2015-11-18 | Lycera Corp | Saturated acylguanidine for the inhibition of F1F0-ATPASE |
| WO2015089149A1 (en) | 2013-12-10 | 2015-06-18 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof |
| AU2014363907B2 (en) | 2013-12-10 | 2018-10-04 | Lycera Corporation | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
| JP2016539983A (ja) * | 2013-12-10 | 2016-12-22 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | アルキルピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途 |
-
2014
- 2014-12-10 AU AU2014363907A patent/AU2014363907B2/en not_active Ceased
- 2014-12-10 EP EP14870064.4A patent/EP3080087B1/en not_active Not-in-force
- 2014-12-10 WO PCT/US2014/069494 patent/WO2015089152A1/en not_active Ceased
- 2014-12-10 CA CA2931792A patent/CA2931792A1/en not_active Abandoned
- 2014-12-10 US US15/101,126 patent/US9914706B2/en not_active Expired - Fee Related
- 2014-12-10 JP JP2016538082A patent/JP2016539993A/ja active Pending
-
2018
- 2018-02-14 US US15/896,378 patent/US10392350B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507581A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2016501250A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2015535277A5 (enExample) | ||
| JP2014507464A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2012111770A5 (enExample) | ||
| CA2668997A1 (en) | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors | |
| JP2016525075A5 (enExample) | ||
| JP2014509647A5 (enExample) | ||
| JP2016530338A5 (enExample) | ||
| JP2012140432A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2013540712A5 (enExample) | ||
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
| JP2017517538A5 (enExample) | ||
| JP2016539993A5 (enExample) | ||
| JP2013502441A5 (enExample) | ||
| JP2016539985A5 (enExample) | ||
| JP2014505032A5 (enExample) | ||
| JP2015501327A5 (enExample) |